reata pharmaceuticals stock forecast

Tuesday, October 25, 2022 Edit

The Score for RETA is 37 which is 26 below its historic median score of 50 and infers higher risk than normal. The average Reata Pharmaceuticals stock price prediction forecasts a.

Fquj9dmivus4um

Reata Pharmaceuticals Stock Prediction.

. Reata Pharmaceuticals Stock Prediction. Reata Pharmaceuticals boosted investment sharply in the last year with cash burn ramping by 76. The Reata Pharmaceuticals stock prediction results are shown below and presented as a graph table and text information.

Reata Pharmaceuticals stock forecast for 2025 by month. The best long-term short-term Reata Pharmaceuticals share price prognosis for 2021 2022 2023. On average Wall Street analysts predict.

The current Reata Pharmaceuticals RETA share price is 2875. The average Reata Pharmaceuticals stock forecast 2023 represents a 5058 increase from the last price of 362099990844727. The Reata Pharmaceuticals stock prediction results are shown below and presented as a graph table and text information.

Reata Pharmaceuticals Stock Forecast 2R3 stock price prediction. Reata Pharmaceuticals stock monthly and. RETA stock quote history news and other vital information to help you with your stock trading and investing.

Based on 6 Wall Street analysts offering 12 month price targets for Reata Pharmaceuticals in the last 3 months. Target levels support and resistance levels. Of course the truly verdant revenue growth of 104 in that time may well.

Reata Pharmaceuticals Inc. Reata Pharmaceuticals Stock Forecast 10-01-2022. Reata Pharmaceuticals Inc.

The 10 analysts offering 12-month price forecasts for Reata Pharmaceuticals Inc have a median target of 4900 with a high estimate of 7600 and a low. 161 rows About the Reata Pharmaceuticals Inc. NASDAQRETAs beta value is holding at 107 while the average true range ATR indicator is currently reading 217.

That Reata Pharmaceuticalss share price could reach 4383 by Aug 9 2023. RETA share price prediction for 2022 2023 2024 2025 2026 and 2027. Reata Pharmaceuticals stock forecasts are adjusted.

The average price target is 5125 with a high. Reata Pharmaceuticals RETA stock. Reata Pharmaceuticals Stock Prediction.

As of 2022 October 09 Sunday current price of RETA stock is 23780 and our data indicates that the. Forecast and historical charts. Find the latest Reata Pharmaceuticals Inc.

Reata Pharmaceuticals Inc RETA Stock Forecast By Analysts Moderate Buy Analysts Recommendations for Reata Pharmaceuticals Inc RETA is based on 15 Institutional Analyst. For Reata Pharmaceuticals stock forecast for 2025 12. RETA one year forecast.

Technical analysis historical chart. Forecast target price for 10-01-2022. Positive dynamics for Reata Pharmaceuticals shares will prevail with possible.

Target prices for 2022 2023 2024. Reata Pharmaceuticals Stock Prediction. RETA Stock Price Prediction.

Short-term and long-term forecasts for Reata Pharmaceuticals shares. Reata Pharmaceuticals stock forecasts are adjusted.

Reata Pharmaceuticals Inc Reta Stock Price Us75615p1030 Marketscreener

Reta Stock Forecast Price News Reata Pharmaceuticals

Irving Biotech Reata Pharmaceuticals Sets Terms For Initial Public Offering Dallas Business Journal

Reata Reta Up After Fda Scraps Adcom Meeting For Nda Filing Nasdaq

A 2vg8zwifst4m

85 Biggest Movers From Yesterday Markets Insider

Reata Pharmaceuticals Inc Trade Ideas Nasdaq Reta Tradingview

Reata Pharma Sees Relative Strength Rating Rise To 71 Investor S Business Daily

Shareholder Alert Robbins Llp Informs Investors Of Class Action Against Reata Pharmaceuticals Inc Reta Business Wire

Reata Pharma Finally We Have A Pdufa Nasdaq Reta Seeking Alpha

Reta Def14a 20210610 Htm

Reata Pharmaceuticals Thesis Strengthened Q3 Data Looms Nasdaq Reta Seeking Alpha

Reta Share Price And News Reata Pharmaceuticals Inc Nasdaq

Reata Pharmaceuticals Inc Reta Stock Price Quote News Stock Analysis

Reta Def14a 20210610 Htm

Reata Deadline Alert Bragar Eagel Squire P C Reminds Investors That A Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals Inc And Encourages Investors To Contact The Firm Business Wire